2018
Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Chen PY, Muzumdar M, Dorans KJ, Robbins R, Bhutkar A, Del Rosario A, Mertins P, Qiao J, Schafer AC, Gertler F, Carr S, Jacks T. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Research 2018, 78: 985-1002. PMID: 29279356, PMCID: PMC5837062, DOI: 10.1158/0008-5472.can-17-2129.Peer-Reviewed Original ResearchConceptsMurine PDAC cellsPDAC cellsNontranscriptional mechanismsKRAS inhibitorsGlobal phosphoproteomic profilingActivated KRASHallmark genetic alterationsTranscriptional changesPhosphoproteomic profilingCell signalingCell statesPathway componentsTumor-initiating capacityPancreatic ductal adenocarcinomaTemporal controlGenetic alterationsCell morphologyMechanistic directionsKras expressionKrasCellsProliferative kineticsInhibitorsNovel KRAS inhibitorsAdherence properties
2007
Modeling sporadic loss of heterozygosity in mice by using mosaic analysis with double markers (MADM)
Muzumdar MD, Luo L, Zong H. Modeling sporadic loss of heterozygosity in mice by using mosaic analysis with double markers (MADM). Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 4495-4500. PMID: 17360552, PMCID: PMC1810340, DOI: 10.1073/pnas.0606491104.Peer-Reviewed Original ResearchConceptsTumor suppressor geneHuman cancersDouble markersCyclin-dependent kinase inhibitorLoss of heterozygositySporadic lossKinase inhibitorsMiceSporadic cellsSimilar degreeSomatic activationCancerCell-autonomous controlConcurrent labelingTSG lossCell expansionMarkersCellsProof of principleProtooncogeneMosaic analysisTSG function